» Authors » Hanneke Jansen

Hanneke Jansen

Explore the profile of Hanneke Jansen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 1108
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Rijksen B, Pos F, Hulshof M, Vernooij R, Jansen H, van Andel G, et al.
Eur Urol Focus . 2019 Nov; 7(2):332-339. PMID: 31748122
Background: According to (inter-)national guidelines, (neo-)adjuvant and concurrent androgen deprivation therapy (ADT) in combination with external beam radiotherapy (EBRT) is optional for intermediate-risk prostate cancer (PCa) patients and is the...
2.
Hueting T, Cornel E, Somford D, Jansen H, van Basten J, Pleijhuis R, et al.
Eur Urol Oncol . 2019 Jun; 1(5):411-417. PMID: 31158080
Background: Multiple statistical models predicting lymph node involvement (LNI) in prostate cancer (PCa) exist to support clinical decision-making regarding extended pelvic lymph node dissection (ePLND). Objective: To validate models predicting...
3.
Oude Luttikhuis H, Baur L, Jansen H, Shrewsbury V, OMalley C, Stolk R, et al.
Cochrane Database Syst Rev . 2019 Mar; 3:CD001872. PMID: 30843601
Background: Child and adolescent obesity is increasingly prevalent, and can be associated with significant short- and long-term health consequences. Objectives: To assess the efficacy of lifestyle, drug and surgical interventions...
4.
Jansen H, van Oort I, van Andel G, Wijsman B, Pos F, Hulshof M, et al.
Prostate Cancer Prostatic Dis . 2018 Nov; 22(2):337-343. PMID: 30429595
Background: To provide insight in the treatment variation of very-low-risk prostate cancer patients and to assess the role of hospital-related factors. Methods: All patients diagnosed with very-low-risk prostate cancer (cT1c-cT2a,...
5.
Vos R, van Avendonk M, Jansen H, Goudswaard A, van den Donk M, Gorter K, et al.
Cochrane Database Syst Rev . 2016 Sep; 9:CD006992. PMID: 27640062
Background: It is unclear whether people with type 2 diabetes mellitus on insulin monotherapy who do not achieve adequate glycaemic control should continue insulin as monotherapy or can benefit from...
6.
Kasteleyn M, Vos R, Jansen H, Rutten G
J Diabetes Complications . 2016 May; 30(5):830-3. PMID: 27134032
Aims: To explore differences in clinical characteristics of patients with and without type 2 diabetes (T2DM) hospitalized with a first myocardial infarction (MI). Methods: In this cross-sectional study we examined...
7.
Jansen H, Wijga A, Scholtens S, Koppelman G, Postma D, Brunekreef B, et al.
PLoS One . 2015 Apr; 10(4):e0119615. PMID: 25875773
Objective: HbA1c is associated with cardiovascular risk in persons without diabetes and cardiovascular risk accumulates over the life course. Therefore, insight in factors determining HbA1c from childhood onwards is important....
8.
Kasteleyn M, Wezendonk A, Vos R, Numans M, Jansen H, Rutten G
Fam Pract . 2014 Aug; 31(6):688-93. PMID: 25106412
Background: Secondary prevention is efficient in reducing morbidity and mortality after a myocardial infarction (MI). However, both short-term and long-term mortality after MI remains relativity high in type 2 diabetes...
9.
Kasteleyn M, Gorter K, van Puffelen A, Heijmans M, Vos R, Jansen H, et al.
Prim Care Diabetes . 2014 Jan; 8(3):195-206. PMID: 24389352
Aims: Despite diabetes patients' efforts to control their disease, many of them are confronted with an acute coronary event. This may evoke depressive feelings and self-management may be complicated. According...
10.
Jansen H, den Engelsen C, Rutten G
Metab Syndr Relat Disord . 2013 Feb; 11(3):163-8. PMID: 23438154
Background: Metabolic syndrome is a cluster of risk factors for cardiovascular disease and type 2 diabetes. Physical activity can decrease these risks. Many randomized clinical trials to increase physical activity...